Related Experiment Video

Updated: Jul 16, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic

Antonio Jimeno1, Belen Rubio-Viqueira, Maria L Amador

  • 1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, School of Medicine, The Johns Hopkins University, The Baunting and Blaustein Cancer Research Building, 1650 Orleans Street, Room 1M89, Baltimore, MD 21231, USA.

Molecular Cancer Therapeutics
|March 17, 2007
PubMed

Insights

Combining epidermal growth factor receptor inhibitors with MAPK inhibitors shows promise for treating biliary and pancreatic cancers. This targeted therapy approach effectively inhibits cancer growth in resistant tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Biliary and pancreatic cancers exhibit resistance to targeted therapies like epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).
  • Understanding the molecular mechanisms of resistance is crucial for developing effective combination therapies.

Purpose of the Study:

  • To identify gene expression profiles associated with resistance to EGFR-TKIs in biliary cancer cell lines.
  • To evaluate the efficacy of combining an EGFR inhibitor with a mitogen-activated protein kinase (MAPK) pathway inhibitor for treating biliary and pancreatic cancers.

Main Methods:

  • Global gene expression profiling using Affymetrix U133A microarrays.
  • Validation of gene expression using Western blot and immunohistochemistry.
  • In vitro and in vivo testing of combination therapy (gefitinib + CI-1040) in resistant cancer models and patient-derived xenografts.

Main Results:

  • A set of 32 genes, including those in the Ras/Raf/MAPK pathway, were overexpressed in resistant cells.
  • Gefitinib alone did not inhibit the MAPK pathway in resistant cell lines.
  • Combined gefitinib and CI-1040 inhibited the MAPK pathway and demonstrated significant antitumor effects in vitro and in vivo, outperforming single-agent treatments.

Conclusions:

  • Global gene expression analysis is valuable for designing rational drug combinations.
  • Combined EGFR and MAPK inhibition offers a promising therapeutic strategy for biliary and pancreatic cancers resistant to single-agent therapies.
  • This combination warrants clinical investigation for biliary and pancreatic cancer treatment.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...